Stempoint Capital LP Purchases Shares of 753,520 Zura Bio Limited $ZURA

Stempoint Capital LP acquired a new stake in Zura Bio Limited (NASDAQ:ZURA) in the 1st quarter, Holdings Channel reports. The firm acquired 753,520 shares of the company’s stock, valued at approximately $4,483,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ZURA. Bank of America Corp DE increased its stake in shares of Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after buying an additional 9,966 shares during the period. AQR Capital Management LLC acquired a new stake in Zura Bio in the first quarter valued at approximately $72,000. JPMorgan Chase & Co. lifted its stake in Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares during the last quarter. Jane Street Group LLC purchased a new position in Zura Bio in the second quarter worth approximately $113,000. Finally, UBS Group AG grew its holdings in Zura Bio by 878.3% during the 3rd quarter. UBS Group AG now owns 305,329 shares of the company’s stock worth $1,322,000 after acquiring an additional 274,118 shares in the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZURA has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th. William Blair assumed coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating for the company. Wedbush reiterated an “outperform” rating and set a $15.00 target price on shares of Zura Bio in a research note on Wednesday, July 1st. Finally, Wall Street Zen lowered Zura Bio from a “sell” rating to a “strong sell” rating in a report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Stock Down 4.2%

ZURA stock opened at $5.31 on Thursday. The business has a 50 day moving average price of $4.63 and a 200 day moving average price of $5.38. The stock has a market cap of $503.81 million, a price-to-earnings ratio of -4.87 and a beta of -0.03. Zura Bio Limited has a fifty-two week low of $1.35 and a fifty-two week high of $7.44.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). As a group, sell-side analysts anticipate that Zura Bio Limited will post -0.76 EPS for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.